Results about: breast cancer

<p>Gomis</p>

Intricate signalling networks control cell division, differentiation, movement, organization and death. Understanding how cells read and transform these signals into changes in cell behaviour is a major research focus of our group.

An international consortium identifies the breast cancer patients who would benefit from a treatment to prevent metastasis

A study published in the Lancet Oncology by an international team led by Prof Rob E. Coleman (University of Sheffield) and Prof Roger R. Gomis (IRB Barcelona) identifies the effect of MAF amplification on the outcome of treatment with adjuvant zoledronic acid in early breast cancer.

This new knowledge may be key to the early detection of patients who would benefit from zoledronic acid and those who should be spared, and both reduce disease recurrence and deaths from breast cancer.

Inbiomotion, an IRB Barcelona spin off company and financed by venture investors Ysios Capital and Caixa Capital Risc, will soon start a confirmatory trial.

Three innovation projects at IRB Barcelona are granted funding for market development

The labs headed by Angel R. Nebreda, Ernest Giralt and Roger Gomis secure funding for further development of three medical applications.

The three projects will receive 220,000 euros from the "Knowledge Industry" programme, which is run by the Catalan Government and cofunded by ERDFs.

A study reveals the biological changes in breast cancer between the primary tumour and metastases

Researchers at IDIBAPS and IRB Barcelona have described in Cancer Research, that the longer the time from the onset of the tumour to the development of metastasis is, the more aggressive this cancer becomes.